Abstract

Human papillomavirus (HPV)-induced cervical cancer is a major health issue among women from the poorly/under-developed sectors of the world. It accounts for a high-mortality rate because of its late diagnosis and poor prognosis. Initial establishment and subsequent progression of this form of cancer are completely dependent on two major oncogenes E6 and E7, which are expressed constitutively leading to tumorigenesis. Thus, manipulation of these genes represents the most successful form of cervical cancer therapy. In the present article, information on structural, functional, and clinical dimensions of E6 and E7 activity has been reviewed. The genome organization and protein structure of E6 and E7 have been discussed followed by their mechanism to establish the six major cancer hallmarks in cervical tissues for tumor propagation. The later section of this review article deals with the different modes of therapeutics, which functions by deregulating E6 and E7 activity. Since E6 and E7 are the biomarkers of a cervical cancer cell and are the ones driving the cancer progression, therapeutic approaches targeting E6 and E7 have been proved to be highly efficient in terms of focused removal of abnormally propagating malignant cells. Therapeutics including different forms of vaccines to advanced genome editing techniques, which suppress E6 and E7 activity, have been found to successfully bring down the population of cervical cancer cells infected with HPV. T-cell mediated immunotherapy is another upcoming successful form of treatment to eradicate HPV-infected tumorigenic cells. Additionally, therapeutics using natural compounds from plants or other natural repositories, i.e., phytotherapeutic approaches have also been reviewed here, which prove their anticancer potential through E6 and E7 inhibitory effects. Thus, E6 and E7 repression through any of these methods is a significant approach toward cervical cancer therapy, described in details in this review along with an insight into the signaling pathways and molecular mechanistic of E6 and E7 action.

Highlights

  • Cervical cancer is continuing to rise as a global concern with around 570,000 cases diagnosed and 311,000 deaths registered in the year 2018 (Bray et al, 2018)

  • This review discusses in detail about the human papillomavirus genome and its major oncogenes E6 and E7, i.e., the builders of six hallmarks of cancer along with a deeper insight into the clinical implications of E6 and E7 disruption through modern day genome editing techniques or phytotherapeutic methods

  • human papillomaviral (HPV) E6 can bind to the LxxLL consensus sequence in the conserved domain of E6AP to form a heterotrimeric complex of E6/E6AP/p53, leading to the degradation of p53

Read more

Summary

Asmita Pal and Rita Kundu*

Human papillomavirus (HPV)-induced cervical cancer is a major health issue among women from the poorly/under-developed sectors of the world. Initial establishment and subsequent progression of this form of cancer are completely dependent on two major oncogenes E6 and E7, which are expressed constitutively leading to tumorigenesis. Manipulation of these genes represents the most successful form of cervical cancer therapy. Therapeutics including different forms of vaccines to advanced genome editing techniques, which suppress E6 and E7 activity, have been found to successfully bring down the population of cervical cancer cells infected with HPV.

INTRODUCTION
HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER
HUMAN PAPILLOMAVIRUS GENOME AND ITS INTEGRATION INTO THE HOST CELLULAR GENOME
Evasion of Growth Suppressors
Resisting Cell Death
Sustained Proliferative Signaling
Enabling Replicative Immortality
Activation of Invasion and Metastasis
Angiogenesis Induction
Genome Editing With Programmable Nucleases
CONCLUSION
Findings
Withania somnifera
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call